Czech and Slovak DTH services Skylink and CS Link are moving forward with plans to migrate their subscriber base to Irdeto conditional access.The pair have begun reducing the number of channels available via the legacy Cryptoworks CA system ahead of withdrawing its support for Cryptoworks cards at the end of this year. Pay TV HD services including HBO, CS Film and CS Mini, CS TV, Hustler and Man-X will be switched off on Cryptoworks devices at the end of June, while SD pay services will cease to be available at the end of September. Free-to-air services will continue to be available until 2013.Subscribers to the services, which were recently unified under the common ownership of Belgium’s M7 Group, can swap their Cryptoworks cards for Irdeto cards for a fee. Skylink customers who fulfill certain conditions can obtain a replacement card free of charge.
Scottish commercial broadcaster STV has launched its video-on-demand service, STV Player, on Virgin TV set-tops from Liberty Global-owned cable operator Virgin Media.The move, which follows the signing of a four-year strategic partnership deal between STV and Virgin Media earlier this year, will integrate the STV Player app and STV catch-up programming on Virgin TV set top boxes ahead of the Christmas viewing season.STV player will offer 30-day catch-up of most content on Virgin Media, with all catch-up content available in HD from the operator’s EPG.The agreement means that Virgin TV customers will be able to view exclusive regional STV programming on their set top boxes, including STV News at Six and popular current affairs programme, Scotland Tonight, as well as over 1,200 episodes of shows from the STV archives, including Taggart and Rebus.Virgin TV customers will also be able to view content from STV’s new content partners including pre-school kids TV app Hopster and youth-focused digital broadcaster, Little Dot Studios. STV will be announcing more content partnerships next year.Separately, Virgin Media will also broadcast STV in HD in all cabled STV regions – Glasgow, Edinburgh and Dundee – from early next year, replacing the single STV HD service currently available.Richard Williams, STV’s managing director, digital, said: “We are delighted to be able to enhance our offering to Virgin TV customers right across Scotland as part of this innovative partnership. Launching STV Player on this popular platform means Virgin Media customers in Scotland can access their favourite STV shows however and whenever they want, from I’m a Celebrity to Scotland Tonight to our ever-popular soaps, Coronation Street and Emmerdale.”David Bouchier, chief digital entertainment officer at Virgin Media, said: “The addition of STV Player to the Virgin TV platform gives our customers the full range of STV’s programming on demand for the first time, which is great news for our customers in Scotland. This means our viewers can watch STV on demand in HD at the touch of a button. It’s all part of our continued investment in our Scottish TV customers with more exciting announcements to come.”
Mediaset may move to consolidate its Spanish operation as the first step of a strategy to create a pan-European TV powerhouse, according to Italian financial daily Il Sole 24 Ore.According to the newspaper, the Italian broadcaster is mulling a plan to acquire the 48.4% of Mediaset España that it does not already own as the first step towards creating a consolidated pan-European broadcaster.Shares in Mediaset España, which controls leading commercial channels Telecinco and Cuatro, rose on the news.The latest report of plans to consolidate the Spanish outfit follow a similar report by Bloomberg last September that also saw Mediaset España’s share price rise, but which was denied by Mediaset.According to Il Sole 24 Ore, the acquisition of Mediaset España could be followed by moves to establish a pan-European powerhouse, possibly with German commercial broadcaster ProSiebenSat.1 and France’s TF1.Mediaset already has a relationship with those two broadcasters in the shape of the European Media Alliance, created four years ago to foster closer collaboration between European broadcasters in the face of enhanced threats from digital players such as Netflix and Amazon.The latest report of Mediaset’s interest in its Spanish operation came as Morgan Stanley published a note revising its price target for the broadcaster downwards in the light of a need for additional investment to combat the threat presented by digital players and an ongoing softening of the European advertising market. According to Morgan Stanley, the broadcasters most immediately impacted by the combination of a need to make substantial investment and the advertising downturn are Mediaset and its putative German partner ProSiebenSat.1.Mediaset VP and CEO Pier Silvio Berlusconi last year said that the broadcaster was working on a plan to forge an alliance with other European broadcasters, with it taking a leading role. Berlusconi specifically ruled out working with French media giant and Canal+ owner Vivendi. The latter had been Mediaset’s preferred partner for a pan-European strategy until the pair spectacularly fell out over Vivendi’s withdrawal from an agreement to purchase Mediaset Premium in 2016.
Source:http://www.ntu.edu.sg/ Reviewed by James Ives, M.Psych. (Editor)Nov 9 2018Nanyang Technological University, Singapore (NTU Singapore) is pioneering the use of 3D-printed anatomical specimens for medical education in Singapore.Just last month, students at the Lee Kong Chian School of Medicine (LKCMedicine), jointly set up by NTU Singapore and Imperial College London, started learning anatomy with 3D-printed specimens.A collaboration between LKCMedicine and NTU’s Singapore Centre for 3D Printing, these 3D-printed specimens come in varying materials, colors, hardness and flexibility to mimic the properties of anatomical structures in a real human body – a first in Singapore.The made-in-NTU 3D-printed specimens are the latest example of NTU turning to innovative learning tools to prepare its medical students, as the medical education landscape shifts in tandem with the influx of digital technologies.LKCMedicine is also looking into other pedagogical approaches such as a medical tutor powered by artificial intelligence and a mobile app where virtual 3D animated specimens can be accessed. (See Annex A)Such innovative teaching tools are highlighted at the Transform Medical Education (Transform MedEd), an inaugural two-day conference that looks at how new pedagogical approaches and the latest technologies are shaping the future of medical education and healthcare practice.Jointly organized by LKCMedicine and Imperial College London School of Medicine, the conference provides a platform for local and international thought leaders to interact with educators, scientists and students. The interactive program will focus on the latest advances in the science and practice of medical education, and participants will share perspectives on how innovations in technology and pedagogy can transform the way health professionals learn.NTU President Professor Subra Suresh said, “As the boundaries between the physical, digital, and biological words become increasingly blurred, we should examine as to how we can use technology to break down the walls between classrooms and clinical learning environments. With digital technologies such as artificial intelligence, data science, 3D printing, and augmented reality playing an increasingly significant role in medical care, we want to make sure that we continuously improve teaching and learning methods and their outcomes for students at NTU.”This means leveraging resources on the NTU Smart Campus and our strengths in areas of computing and computer science to integrate the latest technologies into our pedagogical approach, so that we can help train our medical students to become well-prepared, confident and capable doctors.”Professor Simone Buitendijk, Vice-Provost (Education) at Imperial College London, said: “This international conference reflects Singapore’s status as a global hub for medical education.Related StoriesIt is okay for women with lupus to get pregnant with proper care, says new studyAn active brain and body associated with reduced risk of dementiaArthroscopy more accurate than MRI for chondral defects of the knee, study finds”From artificial intelligence to curriculum-mapping software, collaboration between Imperial College London and NTU is changing the way future doctors learn. We embrace the challenge of keeping pace with shifting global health priorities – from caring for aging populations to meeting the rising demand for personalized medicine.”As demonstrated at this conference, educators and industry stand ready with an abundance of ideas that will improve patient outcomes for the better.”Over the two days, there will be practical opportunities for participants to enhance their teaching skills and learn about the latest advances in medical education with hands-on workshops, facilitated discussions and presentations by internationally renowned medical educators.Invited speakers include Queen Mary University of London Professor of Medicine and Education Dame Parveen Kumar, who will challenge the conventions of textbook learning in medical education, LKCMedicine Visiting Professor Henk Schmidt who will present a research-informed view of How students learn in the healthcare setting, and IBM Asia Pacific Director of Healthcare & Social Services Ms Farhana Nakhooda, who will talk about augmented clinical intelligence as a new era in healthcare. (See Annex B)LKCMedicine Dean Professor James Best said, “Our mission is to train a new generation of doctors who know how and when to use the latest technology, while never losing sight of what matters the most – the patient, who is at the heart of their care.”To prepare our students to become patient-centred doctors, we at LKCMedicine are harnessing the latest technologies from 3D printing to high-fidelity simulation to offer a modern and interactive medical education, while at the same time retaining the patient’s perspective and experience throughout our curriculum, right from the first few weeks of medical school.”Since it was established in 2010, LKCMedicine has employed innovative technologies and the best teaching practices to deliver a modern medical education.Moving away from the traditional lectures, LKCMedicine adopts the flipped classroom pedagogy, where students learn the course content online before class and face time with professors and classmates is devoted to collaborative learning. In 2013, the school pioneered the use of plastinated specimens, eliminating the need for traditionally preserved cadavers which are in short supply in Singapore.The first batch of LKCMedicine students graduated in 2017 and are now working in the various public hospitals in Singapore.
Image Credit: Africa Studio / Shutterstock By Dr. Ananya Mandal, MDFeb 6 2019A new study has shown that pain relief creams are no better than dummy or placebo creams when it comes to relieving pain. The study titled, “Compounded Topical Pain Creams to Treat Localized Chronic Pain: A Randomized Controlled Trial,” was published in the latest issue of the journal Annals of Internal Medicine. These pain relief creams are prescribed to be applied locally over localized pain sites for pain relief explain the researchers. They come at a relatively high cost but are not better than placebo creams they add. The experts add that there have been concerns regarding the safety of pain relievers and also side effects and abuse potential of opioid pain relievers. This has raised the prescriptions for these compounded pain relievers with no real data regarding their superior efficacy or safety. They have appealed to prescribers as well as users due to the perception of their low rates of side effects due to topical use.This study is a randomized controlled trial from the researchers at the Walter Reed National Military Medical Center. The team included 399 patients with either localized pain that was diagnosed to be due to nerve damage or neuropathic (total of 133 patients) or nociceptive pain or pain due to tissue injury (not nerves) (total of 133 patients) or mixed type of pain (133 patients). The groups were further divided into two and one half was given pain cream compounded specifically for their type of pain or a placebo or dummy cream. The drugs used in the compounded creams were FDA approved and routinely used for pain relief. This included agents such as non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants (such as “ketoprofen, baclofen, cyclobenzaprine, and lidocaine”) for nociceptive pain and anticonvulsants and others (“ketamine, gabapentin, clonidine, and lidocaine”) for nerve pain. For the mixed pain treatment group compounds with “ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine” were used.Related StoriesResearchers survey orthopedic providers to understand factors that drive opioid prescribing practicesStudy shows potential culprit behind LupusEngineered stem cells offer new treatment for metastatic bone cancerPain sensation was evaluated, a month after prescription of the creams. Results showed that there was no significant difference in improvement in pain symptoms with use of compounded pain creams compared to placebo creams. Around 28 percent participants in the placebo group and 36 percent participants in the pain cream group reported pain alleviation. This difference was not deemed to be significant enough for use of pain creams, write the researchers. Further, the compounded pain creams were most expensive compared to other creams, the authors add. Small benefits seen with these creams, they add, are due to the effects on the peripheral nervous system and not due to effects on the central nervous system.Senior study author Dr. Steven Cohen, a pain researcher at Walter Reed National Military Medical Center in Bethesda, Maryland, and Johns Hopkins Medicine in Baltimore in a statement said, “We know from other studies that some of the agents (lidocaine, non-steroidal anti-inflammatory drugs) may be effective for certain types of acute and chronic pain, so it is surprising that the difference here did not reach statistical significance in any of the pain types…This matters because compounded pain creams are much more expensive than prescribed (lidocaine, diclofenac) or over-the-counter (capsaicin) pain creams, but they didn’t provide meaningful benefit compared to placebo cream.” Authors conclude that these compounded pain relieving creams should not be prescribed routinely for treatment of pain.The study was funded and supported by the Centers for Rehabilitation Sciences Research, Defense Health Agency, U.S. Department of Defense. Source:https://annals.org/aim/article-abstract/2724041/compounded-topical-pain-creams-treat-localized-chronic-pain-randomized-controlled
Source:http://cvia-journal.org/ Reviewed by James Ives, M.Psych. (Editor)Mar 1 2019In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women’s Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 349-361(13); DOI: https://doi.org/10.15212/CVIA.2017.0077 Keith C. Ferdinand, MD and Rohan Samson, MD from the Tulane University Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA consider nonobstructive coronary artery disease in women: risk factors and noninvasive diagnostic assessment.The authors review differences in coronary anatomy, microcirculation, vascular tone and differences in the atherosclerosis process while stressing the importance of key risk factors in women such as hypertension, obesity and inflammation and its association not only with sex but ethnicity. Sex-specific differences in the epidemiology and pathophysiology of coronary artery disease and ischemic heart disease are now well recognized. Women with angina more often have nonobstructive coronary artery disease ( NOCAD) compared with men. This patient population carries a significant risk of future cardiovascular events that is not commonly appreciated, often leading to delayed diagnosis and treatment. While coronary microvascular dysfunction plays a central role in the athophysiology of NOCAD in women, other mechanisms of myocardial ischemia are now recognized. Risk factors such as hypertension and obesity disparately affect women and are likely to account for a significant proportion of NOCAD in the coming years. Vascular inflammation is an important pathophysiologic pathway in NOCAD and is a potential therapeutic target. Coronary CT angiography provides a comprehensive assessment of coronary anatomy and plaque morphology and is a reasonable screening test of choice for NOCAD.This article forms part of a special issue on Women’s Cardiovascular Health, guest edited by Gladys P. Velarde. Recent decades have witnessed great progress in the treatment of cardiovascular disease (CVD). Due to improved therapies, preventive strategies and increased public awareness, CVD (stroke, heart failure, ischemic heart disease, peripheral arterial disease and congenital heart disease) mortality has been on the decline over this span of time for both genders. Unfortunately, the decline has been less prominent for women, especially women of color. Once viewed as a man’s disease, CVD remains the leading cause of mortality for women in the United States and is responsible for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age in developing countries. In the United States, CVD far outpaces all other causes of death, including all forms of cancer combined. The statistics are sobering with about one female death in the United States every 80 seconds from CVD. That represents close to 400,000 deaths per year according to the more recent statistics. Of these, more than one quarter of a million women will die this year from ischemic heart disease (IHD) which includes obstructive and non-obstructive coronary disease, and about 64% of women who die suddenly of IHD have no prior symptoms. Despite a significant number of females with known CVD and increased awareness among women of heart disease as their major health threat, a substantial proportion of women (46% as per the most recent American Heart Association survey) remain unaware of their cardiovascular risk and continue to fail to recognize its significance.Related StoriesStudy provides new insight into the heritability of coronary artery diseaseImaging beyond routine angiography may be helpful in women with suspected MI and no obstructive CADEU-funded researchers develop new therapeutic strategy for atherosclerosisThis lack of awareness is more profound (over 60% unaware) among women in higher-risk groups, racial and ethnic minorities, and has changed little in decades.Poorly understood sex/gender differences in pathobiologic mechanisms, clinical presentation, management and application of diagnostic and therapeutic and preventive strategies have contributed to this gap. A critically important factor has been the underrepresentation of women in CVD research to date. In fact, only one-third of CVD clinical trials report sex-specific results despite The Food and Drug Administration regulations requiring sex stratification data, as well as the National Institute of Health recommendations of increased inclusion of women in clinical trials. This makes it difficult for researchers and clinicians to draw accurate conclusions about sex differences in mechanisms of disease, accuracy of specific diagnostic modalities and risks or benefits of a particular drug or device for the treatment of women with CVD. Furthermore, physicians and other healthcare providers continue to underestimate women’s cardiovascular risk, in part because of utilization of traditional approaches which can lead to over-testing or inappropriate risk assessment without accurate differentiating who is truly at risk and inadequate use of preventive therapies for women.The goal of this special edition Cardiovascular Innovations and Applications is to shed some light on specific topics that dominate the spectrum of CVD in women.
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. The tech group’s new executive is Alicia Boler Davis, who has been head of GM’s global manufacturing operations.Amazon had no immediate comment on the hiring of Davis, reported earlier by CNBC.GM said in a statement earlier Thursday that Davis was leaving “to pursue other opportunities” after 25 years with the Detroit auto giant.Amazon, which has moved beyond its online retail roots to cloud computing, streaming media and artificial intelligence, said in mid-February it was leading a $700 million investment round in Rivian, a young self-driving auto technology firm.The potential Tesla rival late last year unveiled an electric pickup truck and an electric sport utility vehicle at an auto show in Los Angeles.Amazon has also invested in the autonomous driving tech firm Aurora Innovation, founded by former Google, Tesla and Uber executives, and it has deployed its own autonomous delivery robots.While Amazon has not outlined any specific plans in the auto sector, it has invested heavily in logistics, with its own fleet of aircraft and vehicles to help speed its parcel deliveries.It has also tested drone deliveries, and could use other kinds of autonomous vehicles as part of its logistics operations, as part of efforts to reduce the cost of “last mile” transport. © 2019 AFP Amazon has hired a top General Motors executive, a source familiar with the move said Thursday, in a further sign of the technology giant’s likely expansion into autonomous vehicles. Amazon invests in electric vehicle startup Rivian Explore further Amazon’s hiring of a top executive from General Motors suggests the US tech giant is making further moves toward autonomous vehicles for its extensive logistics network Citation: Amazon steers further toward autos, hires GM executive (2019, February 28) retrieved 17 July 2019 from https://phys.org/news/2019-02-amazon-autos-hires-gm.html
SHARE SHARE EMAIL A file photo of DV Sadananda Gowda May 30, 2019 COMMENTS COMMENT SHARE Three newly elected MPs from Karnataka will be taking oath as members of Union Council of Ministers, along with Prime Minister Narendra Modi today.They are DV Sadananda Gowda, who was a member of the Modi Cabinet earlier, Pralhad Joshi, a four-time MP from Dharwad and Suresh Angadi, four-time MP from Belgaum. The three MPs announced their induction into the Council of Ministers on Twitter. I congratulate shri @JoshiPralhad ji and @AngadiMp ji for being selected as ministers in @narendramodi ji second phase government. As team we will work together for Nation and the state . I thank @AmitShah ji and @BSYBJP ji once again.and thank every supporter on this occasion.— Sadananda Gowda (@DVSBJP) May 30, 2019 “I congratulate shri @JoshiPralhad ji and @AngadiMp ji for being selected as ministers in @narendramodi ji second phase government. As team we will work together for Nation and the state. I thank @AmitShah ji and @BSYBJP ji once again and thank every supporter on this occasion,” Gowda, a former chief minister of Karnataka, tweeted.In a tweet in Kannada, Angadi thanked BJP president Amit Shah and state unit chief B S Yeddyurappa for providing an opportunity for him to serve in the Cabinet of Modi, who is the “country’s pride”.Thanking people of his constituency Belgaum, he also shared pictures of celebrations in his home district.Joshi, who has served as a Karnataka BJP president in the past, tweeted, “I am thankful to @narendramodi ji for giving me opportunity to work with him as central minister. I also thank our national president @AmitShah ji and state president @BSYBJP ji and all other leaders of party for this opportunity.I also thank every voter of my constituency,” he said.Meanwhile, Nirmala Sitharaman, who served as the Defence Minister in the previous government, is also tipped to be inducted into Modi’s new ministry. She represents Karnataka in the Rajya Sabha. Published on